B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Discontinuing tyrosine kinase inhibitor maintenance after extended complete molecular response should only be attempted as part of a clinical trial, the researchers say.

An 8-year-old boy fighting Leukemia in New Jersey lived his dream of becoming a miner thanks to Jersey Mike's and Make-A-Wish ...

To know 8-year-old Brielle Ambabo is to love her. Her silly personality, upbeat attitude and countless jokes are sure to ...

Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

Zavier Sexton, Graham Smith, Bryce Miller and Natalie Vulhop were honored as young heroes at the 2025 CBJ Foundation ...

A young girl from Amsterdam has died after a long hard-fought battle with leukemia.10-year-old Portia Robles died Saturday ...

Imagine one day of your life, completely normal. And the next – your entire life is dedicated to your child’s survival.

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...